The therapeutic potential of renin angiotensin aldosterone system (RAAS) in chronic pain: from preclinical studies to clinical trials. (3rd March 2016)

• Record Type: Journal Article
• Authors: Bessaguet, Flavien; Magy, Laurent; Desmoulière, Alexis; Demiot, Claire
• Is Part Of: Expert review of neurotherapeutics. Volume 16:Number 3(2016)
• Page Start: 331
• Page End: 339
• Publication Date: 2016-03-03
• Subjects: Pain -- renin-angiotensin-aldosterone system; Neuropharmacology -- Periodicals; 615.7805
• DOI: 10.1586/14737175.2016.1150179
• Languages: English
• ISSNs: 1473-7175

Abstract

ABSTRACT: The prevalence rate of chronic pain is 15% to 25% in adults while the therapeutic arsenal is still insufficient, especially in relieving neuropathic pain. Peripheral pain transmission is conducted by the small Aδ and C sensory nerve fibres. They express elements from the renin-angiotensin-aldosterone system (RAAS), a well-known blood pressure regulator. Recently, studies have demonstrated the role of angiotensin II, its derivatives and aldosterone in the modulation of pain perception, by interacting with receptors expressed by sensory nerve fibres or through the central nervous system. Here, we assess the effects of RAAS modulators in the conduction of pain with molecular, preclinical and clinical approaches, in normal or pathological conditions. Currently, some clinical studies have been carried out on the pain-relieving effect of RAAS modulators and suggest their potential in the management of chronic, inflammatory or neuropathic pain.